ArticleCurrent treatment options in neurology2025
Update on the Treatment of Autonomic Disorders.
Article in Current treatment options in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Purposeof Review: Autonomic disorders disrupt homeostasis and cause symptoms such as orthostatic hypotension, urinary urgency, bladder overfilling, sexual dysfunction, constipation, and gastroparesis. Pathophysiologic mechanisms include neurodegeneration, autoimmunity, toxic exposure, medication-induced, and an array of others. Despite the lack of disease-modifying treatments for the most common etiologies, there is a plethora of therapeutic options available to treat the manifestations of dysautonomia. Here we review established and recent therapeutic strategies available for dysautonomia. We also provide a general schema to approach the management of this class of disorders in the clinical setting. Recent Findings: New emerging neuromodulatory devices are showing promise in treating dysautonomic orthostatic hypotension (spinal cord stimulators), urinary dysfunction (tibial and sacral nerve stimulators), sexual dysfunction (percutaneous perineal and sacral nerve stimulation), constipation (sacral anterior root stimulation), and gastroparesis (gastric electrical stimulation). However, most of these approaches are either experimental or not yet widely implemented. Recent medications are often more effective and/or better tolerated than older ones. These include droxidopa for orthostatic hypotension, β-3-adrenergic agonists for spastic bladder, and prucalopride, elobixibat and linaclotide for constipation. Summary: Autonomic disorders manifest with symptoms of homeostatic dysfunction. A wide variety of central and peripheral nervous system disorders cause dysautonomia. While the treatment of each specific disorder varies based on etiology, strategies overlap to manage dysautonomia. Treatments are divided into non-pharmacological, pharmacological, and neuromodulatory strategies. Here, we focus on the most common issues encountered in clinical practice and propose a stepwise approach to manage common symptoms that frequently integrates all three strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.